Exploring innovative approaches in cancer immunotherapy by exploiting the role of translational readthrough-inducing drugs

Abstract

Cancer immunotherapy has dramatically reshaped the oncology therapeutic landscape by harnessing the immune system to recognize and eliminate tumor cells. Yet, a persistent challenge remains: the insufficient presentation of tumor-specific antigens that can trigger a robust, selective immune response. In this issue of Molecular Therapy, Lejeune and colleagues explored a novel approach to enhance tumor immunogenicity through translational readthrough of premature termination codons (PTCs).